Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Amylin Pharmaceuticals
So what: With the partnership dissolving, Amylin faces higher costs for marketing diabetes treatment Byetta and inherits rights to the drug Bydureon, which, if approved, could allow diabetes sufferers to cut injections to just once weekly. Lilly's linagliptin is designed to compete with both Byetta and Bydureon, Bloomberg reports.
Now what: Investors are selling into the unknowns -- specifically, what higher costs will do Amylin's improving profit margins. Do you agree with the skeptics? Or would you buy shares of Amylin Pharmaceuticals at current prices? Please weigh in using the comments box below.
Interested in more information about Amylin Pharmaceuticals? Add it to your watchlist.
Fool contributor Tim Beyers is a member of the Motley Fool Rule Breakers stock-picking team. He didn't own shares in any of the companies mentioned in this article at the time of publication. Check out Tim's portfolio holdings and Foolish writings, or connect with him on Google+ or Twitter, where he goes by @milehighfool. You can also get his insights delivered directly to your RSS reader.
Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Eli Lilly & Co. at J.P. Morgan: 5 Things Investors Will Want to Know
What's Lilly's next stage of growth? CEO Dave Ricks answered this question and more at the J.P. Morgan Healthcare Conference.
Better Buy: Eli Lilly and Co. vs. Merck & Co., Inc.
Find out which big American pharma is best suited to provide big gains in the years to come.
Donald Trump's Nominee for HHS Secretary Causes a Tumble in Biotech Stocks
Worry about whether drug pricing will return to the forefront in Washington, D.C. is increasing following Donald Trump's nomination of a drug-industry insider as his next Department of Health and Human Services secretary.